Bristol Myers Squibb (BMY) to Post Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $1.60 per share and revenue of $11.7389 billion for the quarter. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Parties can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:15 AM ET.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the company earned $1.80 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. On average, analysts expect Bristol Myers Squibb to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Stock Up 1.7%

NYSE BMY opened at $63.65 on Wednesday. Bristol Myers Squibb has a one year low of $42.52 and a one year high of $64.96. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The business has a fifty day moving average price of $57.70 and a 200 day moving average price of $58.17. The company has a market cap of $129.97 billion, a P/E ratio of 17.88, a P/E/G ratio of 0.18 and a beta of 0.23.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be issued a $0.63 dividend. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BMY shares. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a research report on Monday, July 6th. Raymond James Financial reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a report on Friday, July 10th. Finally, UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Eight investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $61.25.

Institutional Investors Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently modified their holdings of the company. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb in the second quarter valued at approximately $25,000. Swiss RE Ltd. purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $25,000. JPL Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at $36,000. Turning Point Benefit Group Inc. purchased a new stake in shares of Bristol Myers Squibb during the 3rd quarter worth $40,000. Finally, Quarry LP purchased a new position in Bristol Myers Squibb in the third quarter valued at $48,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.